Clinical Evidence: Which Wegovy or Mounjaro Results Matter Most?
UK Clinical Trial Evidence: Wegovy or Mounjaro Better Performance Data
When evaluating whether Wegovy or Mounjaro might be better suited to your weight management goals, examining the clinical evidence provides crucial insights. In the landmark STEP 1 trial, patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP 5 trial demonstrated sustained results, with patients maintaining ~clinically studied weight loss at 2 years when continuing treatment.
Mounjaro (tirzepatide) operates through a different mechanism as a dual GIP and GLP-1 receptor agonist, while Wegovy (semaglutide) targets GLP-1 receptors specifically. Both medications require dose escalation protocols and ongoing lifestyle modifications to achieve optimal results. Your prescriber can evaluate which mechanism might align better with your individual health profile and weight management objectives.
Wegovy or Mounjaro Better Value: Complete UK Pricing Breakdown
Understanding the cost structure helps determine whether Wegovy or Mounjaro offers better value for your circumstances. Wegovy pricing at EverydayMeds starts with 0.25mg pens at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to maintenance 2.4mg pens at £209.99. Our Getting Started bundles provide convenient dose progression, such as the Intro Duo (0.25mg & 0.5mg) for £169.99. New customers apply code FIRST40 at checkout, while returning customers use DOSE25 to reach these final prices.
Both Wegovy and Mounjaro require similar clinical oversight and dose escalation periods, making direct cost comparison straightforward. Our 2-pen and 3-pen bundles ensure consistent supply without repeated ordering, particularly valuable during maintenance phases. The Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, offering supply security for established patients.
STEP Trial Results: Wegovy or Mounjaro Better Sustained Outcomes
The STEP clinical programme provides robust evidence for Wegovy's efficacy across diverse patient populations. STEP 2 demonstrated that patients with type 2 diabetes achieved ~clinically studied weight loss, while STEP 3 showed enhanced results (~16%) when combined with intensive behavioural therapy. These trials followed patients for extended periods, providing confidence in sustained outcomes.
The recent SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events (HR 0.80) among patients taking Wegovy, adding important safety data beyond weight loss metrics. This evidence helps inform whether Wegovy or Mounjaro might be better aligned with your broader health considerations and cardiovascular risk profile.
How Wegovy Works: GLP-1 Mechanism in Wegovy or Mounjaro Comparison
Wegovy functions as a GLP-1 receptor agonist, mimicking the natural hormone that signals satiety to your brain after eating. This mechanism reduces appetite and promotes feelings of fullness after smaller meals, supporting adherence to reduced-calorie eating patterns. The medication may also reduce food cravings by acting on brain appetite centres, though individual responses vary. Unlike Mounjaro's dual GIP and GLP-1 action, Wegovy's single-pathway approach provides targeted appetite regulation. Understanding these mechanistic differences helps clarify whether Wegovy or Mounjaro might be better suited to your physiological response patterns and weight management approach.
EverydayMeds Ordering: Wegovy or Mounjaro Better Access Process
Our streamlined process ensures equal access whether you're considering Wegovy or Mounjaro, starting with our comprehensive 3-minute clinical assessment covering medical history, current medications, and weight management goals. Qualified prescribers review your assessment within 3 working days (or 24 hours with express service), determining which medication aligns with your clinical profile. Once approved, we dispatch your medication via next-day delivery using temperature-controlled, cold-chain logistics to maintain product integrity. Our GPhC-registered pharmacy (#9012878) ensures all medications meet UK pharmaceutical standards. This process applies identically to both medications, so your choice between Wegovy or Mounjaro rests purely on clinical and personal preference factors.
Storage Advantages: Wegovy or Mounjaro Better Practical Flexibility
Wegovy offers notable storage advantages that may influence your decision about whether Wegovy or Mounjaro is better for your lifestyle. While both require refrigeration at 2-8°C before first use, Wegovy maintains stability for 6 weeks at room temperature (below 30°C) once removed from the fridge. This compares favourably to Mounjaro's 21-day room temperature limit, providing greater flexibility for travel, work schedules, or temporary storage disruptions. The FlexTouch pen delivery system ensures consistent dosing throughout the mandatory escalation schedule: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg maintenance from week 17 onwards. These practical considerations often prove decisive when determining whether Wegovy or Mounjaro better fits your daily routine.
UK Weight Loss Results: Wegovy or Mounjaro Better Real-World Outcomes
Real-world evidence from UK patients provides additional context beyond controlled trials when evaluating whether Wegovy or Mounjaro delivers better weight loss results. NICE guidance (TA875) recommends Wegovy specifically with specialist weight management support, reflecting confidence in its clinical utility within the NHS framework. Post-marketing surveillance continues to monitor long-term outcomes and safety profiles in diverse UK populations.
Both medications require ongoing commitment to reduced-calorie diets and increased physical activity, with results typically emerging after 12-16 weeks of consistent use. The STEP 1 extension study revealed that patients regained approximately two-thirds of lost weight within one year of discontinuing treatment, emphasising that weight management represents a long-term commitment regardless of whether Wegovy or Mounjaro proves better suited to individual needs.
Expert Recommendation: Wegovy or Mounjaro Better Choice Guidance
Rather than determining whether Wegovy or Mounjaro is definitively better, our clinical approach focuses on personalised matching based on your medical history, lifestyle factors, and treatment preferences. Both medications represent evidence-based options for adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities, as prescription-only medicines requiring clinical oversight. Your prescriber will evaluate factors including existing medical conditions, concurrent medications, injection frequency preferences, and storage requirements to recommend the most suitable option.
Both Wegovy and Mounjaro are available from EverydayMeds following successful clinical assessment, ensuring you have access to whichever option your prescriber determines most appropriate. Our pharmacy team provides ongoing support throughout your treatment journey, regardless of which medication proves better aligned with your individual circumstances. Begin your assessment today using code FIRST40 for new customers, with expert prescriber guidance helping you navigate the Wegovy or Mounjaro decision based on clinical evidence rather than marketing claims.
Start Your Clinical Assessment Today
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
